Skip to content
Austin Top 50
Author:
MapLight Therapeutics, Inc.
MapLight Therapeutics to Participate in Upcoming Investor Conference
November 9, 2026
MapLight Therapeutics Celebrates Co-Founder Dr. Karl Deisseroth on Receipt of 2026 Nobel Prize in Physiology or Medicine for the Development of Optogenetics
October 6, 2026
MapLight Therapeutics to Participate in Upcoming Investor Conference
September 9, 2026
MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
August 13, 2026
MapLight Therapeutics Announces $150 Million Private Placement Financing
August 13, 2026
MapLight Therapeutics Announces Positive Topline Results from Phase 2 ZEPHYR Trial of ML-007C-MA in Schizophrenia
July 27, 2026
MapLight Therapeutics Announces Changes to Board of Directors
June 24, 2026
MapLight Announces Topline Results from Phase 2 IRIS Study for ML-004 in Autism Spectrum Disorder
June 22, 2026
MapLight Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
May 14, 2026